Fruquintinib Combined With TAS-102 Versus Bevacizumab Combined With TAS-102 for Advanced Metastatic Colorectal Cancer
NCT ID: NCT07286695
Last Updated: 2025-12-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
PHASE2
292 participants
INTERVENTIONAL
2025-12-31
2029-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Phase II (safety run-in stage): It aims to evaluate the safety and tolerability of combination therapy-comprising TAS-102 and fruquintinib. TAS-102 was administered at a descending dose level starting from 35 mg/m² each time alongside fixed dose of fruquintinib in mCRC patients who have previously received first-line oxaliplatin and irinotecan-based therapy, or have failed at least two lines of standard chemotherapy regimens.
Phase II (randomized treatment stage): Upon determination of the recommend dose of TAS-102 based on prior data, a randomized controlled study will be conducted in mCRC patients who have previously received first-line oxaliplatin and irinotecan-based therapy, or have failed at least two lines of standard chemotherapy regimens. Patients will be randomly assigned to two arms: experimental arm: Fruquintinib and TAS-102; active comparator arm: Bevacizumab and TAS-102.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Fruquintinib and TAS-102
Fruquintinib Combined With TAS-102
Experimental arm: Fruquintinib: 4mg once daily for 21 days on/7 days off, every 28 days; TAS-102: taken at a recommended dose (based on the results of the safety run-in phase) each time orally twice a day on days 1-5 and 8-12, every 28 days.
Bevacizumab and TAS-102
Bevacizumab combined with TAS-102
Active Comparator: Bevacizumab: 5 mg /kg, intravenously on days 1,15, every 28 days; TAS-102: 35 mg/m²orally twice a day on days 1-5 and 8-12, every 28 days.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Fruquintinib Combined With TAS-102
Experimental arm: Fruquintinib: 4mg once daily for 21 days on/7 days off, every 28 days; TAS-102: taken at a recommended dose (based on the results of the safety run-in phase) each time orally twice a day on days 1-5 and 8-12, every 28 days.
Bevacizumab combined with TAS-102
Active Comparator: Bevacizumab: 5 mg /kg, intravenously on days 1,15, every 28 days; TAS-102: 35 mg/m²orally twice a day on days 1-5 and 8-12, every 28 days.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Aged 18-75 years old (including 18 and 75 years old);
* Diagnosed with advanced metastatic colorectal adenocarcinoma by histopathological examination;
* Patients who have previously received first-line oxaliplatin and irinotecan treatment, or have received and failed at least two lines of standard chemotherapy regimens. These standard treatment regimens must include fluoropyrimidine-based drugs, oxaliplatin and irinotecan (with or without bevacizumab or cetuximab). Treatment failure is defined as disease progression occurring during treatment or within 3 months after the last treatment, or intolerable toxic side effects. Each line of treatment must include one or more chemotherapy drugs administered for ≥1 cycle; if recurrence or metastasis occurs during adjuvant/neoadjuvant treatment or within 6 months after completion of adjuvant/neoadjuvant treatment, the adjuvant/neoadjuvant treatment is considered a failure of first-line chemotherapy for advanced disease;
* Have previously received bevacizumab treatment;
* Must have at least one clear measurable lesion that meets the requirements of the Response Evaluation Criteria in Solid Tumors (RECIST 1.1);
* ECOG performance status of 0-1;
* Expected survival time ≥12 weeks;
* Within 7 days before enrollment, the function of important organs must meet the following requirements (the use of any blood components and cell growth factors within 14 days before enrollment is not allowed):
Absolute neutrophil count ≥1.5×10⁹/L; Platelets ≥80×10⁹/L; Hemoglobin ≥8g/dL; Total bilirubin ≤1.5×ULN (upper limit of normal); ALT (alanine aminotransferase) and AST (aspartate aminotransferase) ≤2.5×ULN (for patients with liver metastasis, ≤5×ULN); Serum creatinine ≤1.5×ULN, and estimated glomerular filtration rate ≥50ml/min; International Normalized Ratio (INR) ≤1.5 or activated partial thromboplastin time (APTT) ≤1.5×ULN;
• Good compliance and willingness to cooperate with follow-up.
Exclusion Criteria
* Previous treatment with TAS-102 or vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKIs) (e.g., anlotinib, apatinib, etc.);
* Participation in other drug clinical trials within 4 weeks before enrollment;
* Have received or is currently receiving other systemic anti-tumor treatments within 4 weeks prior to enrollment;
* Patients with currently uncontrolled hypertension (defined as systolic blood pressure \>140 mmHg and/or diastolic blood pressure \>90 mmHg) despite medication;
* Patients with current diseases or conditions that affect drug absorption, or patients unable to take oral medications;
* Patients with active gastrointestinal diseases such as active gastric and duodenal ulcers, ulcerative colitis, active bleeding from unresected tumors, or other conditions judged by the investigator to potentially cause gastrointestinal bleeding or perforation;
* History of arterial thrombosis or deep vein thrombosis within 6 months before enrollment;
* Patients with evidence or medical history of significant bleeding tendency within 2 months before enrollment, such as melena, hematemesis, hemoptysis, fecal occult blood test (FOBT) result of ++ or above (for patients with FOBT result of + and existing primary lesions, gastroscopy must be performed to rule out bleeding or ulcers before enrollment);
* History of stroke and/or transient ischemic attack within 12 months before enrollment; presence of cardiovascular diseases with significant clinical significance, including but not limited to acute myocardial infarction, severe/unstable angina pectoris, or coronary artery bypass grafting within 6 months before enrollment; congestive heart failure of New York Heart Association (NYHA) class \>2; ventricular arrhythmias requiring medication; left ventricular ejection fraction (LVEF) \<50% (confirmed by echocardiography);
* History of other malignant tumors within the past 5 years, except for fully treated basal cell carcinoma or squamous cell carcinoma of the skin, carcinoma in situ of organs such as the cervix, early non-invasive lung cancer, and non-muscle-invasive bladder cancer;
* Clinically uncontrolled active infections, such as acute pneumonia, active hepatitis B or C (for patients with a history of hepatitis B virus infection, regardless of medication control, hepatitis B virus DNA ≥1×10⁴ copies/mL or \>2000 IU/mL);
* Pregnant women (positive pregnancy test before medication administration) or lactating women;
* Urinalysis showing urine protein ≥2+, or 24-hour urine protein quantitation \>1.0g;
* Patients deemed unsuitable for enrollment in this study by the investigator.
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
AIPING ZHOU
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Aiping Zhou
Role: PRINCIPAL_INVESTIGATOR
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Nukatsuka M, Fujioka A, Nagase H, Tanaka G, Hayashi H. Evaluation of a Novel Combination Therapy, Based on Trifluridine/Tipiracil and Fruquintinib, against Colorectal Cancer. Chemotherapy. 2023;68(2):102-110. doi: 10.1159/000528867. Epub 2023 Jan 9.
Zou J, Wang Y, Xu J, Li J, Wang T, Zhang Y, Bai Y. A Retrospective Study of Trifluridine/Tipiracil with Fruquintinib in Patients with Chemorefractory Metastatic Colorectal Cancer. J Clin Med. 2023 Dec 21;13(1):57. doi: 10.3390/jcm13010057.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HMPL-013-FLAG-C138
Identifier Type: -
Identifier Source: org_study_id